CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company.

Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study for intermediate-risk and high-grade Ta NMIBC, prompting the company to advance two BLA filings in 2027.

PIVOT-006 Trial Delivers 68% Recurrence Risk Reduction

The registrational PIVOT-006 study evaluated adjuvant intravesical cretostimogene following complete tumor resection in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC.

Currently, no U.S. FDA-approved adjuvant treatments exist for this population of roughly 50,000 patients.

PIVOT-006 met its primary endpoint, delivering statistically significant and clinically meaningful improvements over the control arm.

Over a median follow-up of 17 months as of Oct. 26, 2026, cretostimogene reduced recurrence risk by 68% compared with the control arm, achieving a hazard ratio of 0.32.

Patients generally tolerated cretostimogene well, with safety results matching previous studies.

The study recorded no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations.

Expanded BLA Strategy Targets Broader Bladder Cancer Populations

Combined with CG Oncology’s existing data in high-risk BCG-unresponsive NMIBC, the PIVOT-006 results could substantially expand the patient populations eligible for cretostimogene if approved.

Kuan noted that the company is working quickly to finish its BLA filing in intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027.

Following FDA feedback, CG Oncology also plans to expand its initial BLA submission in BCG-unresponsive NMIBC.

Rather than focusing only on patients with CIS with or without papillary tumors, the submission will include patients with high-grade papillary-only disease to achieve a label reflecting the full range of BCG-unresponsive patients.

To incorporate the extra data, CG Oncology now expects to complete that submission before the end of March 2027.

The company has finished all BLA-enabling manufacturing activities supporting both regulatory filings.

CGON Price Action: CG Oncology shares were up 16.25% at $86.49 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.

Image via Shutterstock